Ziprasidone for sedation of the agitated ED patient.
Martel
Marc L
ML
D014150:Antipsychotic Agents / Q000145:classification / Q000627:therapeutic use*; D004329:Droperidol / Q000009:adverse effects; D004348:Drug Labeling; D004638:Emergency Treatment / Q000379:methods* / Q000592:standards; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D010879:Piperazines / Q000145:classification / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011595:Psychomotor Agitation / Q000188:drug therapy*; D013844:Thiazoles / Q000145:classification / Q000627:therapeutic use*; D016171:Torsades de Pointes / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D004329:Droperidol